共查询到20条相似文献,搜索用时 15 毫秒
1.
The “three‐in‐one” formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice 下载免费PDF全文
Rocco Maurizio Zagari Alessandra Romiti Enzo Ierardi Antonietta G. Gravina Alba Panarese Giuseppe Grande Edoardo Savarino Giovanni Maconi Elisa Stasi Leonardo Henry Eusebi Fabio Farinati Rita Conigliaro Franco Bazzoli Marco Romano 《Helicobacter》2018,23(4)
2.
3.
4.
5.
Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton‐pump inhibitor,bismuth, amoxicillin,and metronidazole in Korea 下载免费PDF全文
Jung Wan Choe Sung Woo Jung Seung Young Kim Jong Jin Hyun Young Kul Jung Ja Seol Koo Hyung Joon Yim Sang Woo Lee 《Helicobacter》2018,23(2)
6.
Usefulness of detection of clarithromycin‐resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy 下载免费PDF全文
Takako Osaki Katsuhiro Mabe Cynthia Zaman Hideo Yonezawa Masumi Okuda Kenji Amagai Shinji Fujieda Mitsuhide Goto Wataru Shibata Mototsugu Kato Shigeru Kamiya 《Helicobacter》2017,22(5)
7.
8.
9.
Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China 下载免费PDF全文
Yong Xie Zhenyu Zhang Junbo Hong Wenzhong Liu Hong Lu Yiqi Du Weihong Wang Jianming Xu Xuehong Wang Lijuan Huo Guiying Zhang Chunhui Lan Xiaoyan Li Yanqing Li Hong Wang Guoxin Zhang Yin Zhu Xu Shu Ye Chen Jiangbin Wang Nonghua Lu the Chinese Society of Gastroenterology Chinese Study Group on Helicobacter pylori 《Helicobacter》2018,23(5)
Background
The efficacy of Helicobacter pylori (H. pylori) eradication has steadily declined, primarily because of antibiotic resistance. This study aimed to evaluate the efficacy and safety of furazolidone eradication therapies as initial treatments for H. pylori infection.Methods
A national, multicenter, open‐label, randomized controlled trial was performed at 16 sites across 13 provinces in China to evaluate the efficacy and safety of furazolidone‐containing therapies for H. pylori infection. Treatment naïve patients were randomly assigned to: esomeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, and furazolidone 100 mg twice daily for 10 and 7 days (FAB 10 and FAB 7; the same therapy without bismuth (FA 10 and FA 7). The primary and secondary outcomes were the eradication rate and regimen safety, respectively. Treatment success was assessed by the 13C urea breath test at least 4 weeks after treatment completion.Results
Overall, according to intention‐to‐treat (ITT) analysis, the eradication rates for FAB 10 and FAB 7 were 86.6% (95% confidence interval [CI], 79.9%‐93.2%) and 83.6% (95% CI, 76.3%‐90.9%) and for FA 10 and FA 7 were 82.4% (95% CI, 74.9%‐89.8%) and 77.6% (95% CI, 69.4%‐85.8%), respectively. According to per‐protocol analysis, the overall eradication rates for FAB 10 and FAB 7 were 94.7% (95% CI, 90.3%‐99.1%) and 90.8% (95% CI, 85.1%‐96.5%) and for FA 10 and FA 7 were 90.6% (95% CI, 84.9%‐96.3%) and 85.1% (95% CI, 78.2%‐92.1%), respectively. The overall prevalence of side effects was 8.1%.Conclusions
Furazolidone‐containing therapies, particularly the tested 10‐day quadruple therapy, exhibited satisfactory efficacy and safety. This 10‐day quadruple therapy represents a promising initial treatment strategy for Chinese patients. 相似文献10.
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria 下载免费PDF全文
Ping‐I Hsu Chao‐Yu Pan John Y. Kao Feng‐Woei Tsay Nan‐Jing Peng Sung‐Shuo Kao Huay‐Min Wang Tzung‐Jiun Tsai Deng‐Chyang Wu Chien‐Lin Chen Kuo‐Wang Tsai the Taiwan Acid‐related Disease Study Group 《Helicobacter》2018,23(4)
11.
New bismuth‐containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice 下载免费PDF全文
Antonio Tursi Francesco Di Mario Marilisa Franceschi Rudi De Bastiani Walter Elisei Gianluca Baldassarre Antonio Ferronato Simone Grillo Stefano Landi Maria Zamparella Manuela De Polo Laura Boscariolo Marcello Picchio 《Helicobacter》2017,22(3)
12.
13.
14.
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures 总被引:11,自引:0,他引:11
Background. One week of quadruple therapy including metronidazole is recommended for Helicobacter pylori treatment failures after first line therapy regardless of resistance status. This study investigated whether a quadruple regimen containing furazolidone could be effective as a third‐line (salvage) therapy. Methods. All patients with previous H. pylori treatment failure after a clarithromycin‐metronidazole ± amoxicillin combination plus acid suppression were given lansoprazole 30 mg twice a day (bid), tripotassiumdicitratobismuthate 240 mg bid, tetracycline 1 g bid, metronidazole 400 mg (PPI‐B‐T‐M) three times a day (tid) for 1 week. In the case of treatment failure with this second‐line therapy, the same regimen was applied for 1 week except for using furazolidone 200 mg bid (PPI‐B‐T‐F) instead of metronidazole (sequential study design). Results. Eighteen consecutive patients were treated with PPI‐B‐T‐M. Eleven of those 18 remained H. pylori positive (38.9% cured). Pretherapeutic metronidazole resistance was associated with a lower probability of eradication success (10% vs. 75%, p= .04). Ten of these 11 patients agreed to be retreated by PPI‐B‐T‐F. Final cure of H. pylori with PPI‐B‐T‐F was achieved in 9/10 patients (90%) nonresponsive to PPI‐B‐T‐M. Conclusions. In the presence of metronidazole resistance, PPI‐B‐T‐M as a recommended second‐line therapy by the Maastricht consensus conference achieved unacceptable low cure rates in our metronidazole pretreated population. In this population, metronidazole based second‐line quadruple therapy may be best suited in case of a metronidazole‐free first line‐regimen (e.g. PPI‐clarithromycin‐amoxicillin) or a low prevalence of metronidazole resistance. Furazolidone in the PPI‐B‐T‐F combination does not have a cross‐resistance potential to metronidazole and is a promising salvage option after a failed PPI‐B‐T‐M regimen. 相似文献
15.
Systematic review with meta‐analysis: Vonoprazan,a potent acid blocker,is superior to proton‐pump inhibitors for eradication of clarithromycin‐resistant strains of Helicobacter pylori 下载免费PDF全文
Min Li Tadayuki Oshima Tomoki Horikawa Katsuyuki Tozawa Toshihiko Tomita Hirokazu Fukui Jiro Watari Hiroto Miwa 《Helicobacter》2018,23(4)
16.
17.
18.
Marco Romano Antonietta Gerarda Gravina Gerardo Nardone Alessandro Federico Marcello Dallio Marco Martorano Caterina Mucherino Alessandra Romiti Luciana Avallone Lucia Granata Katerina Priadko Debora Compare Concetta Tuccillo Maria Raffaella Romito Dolores Sgambato Agnese Miranda Lorenzo Romano Carmelina Loguercio Franco Bazzoli Rocco Maurizio Zagari 《Helicobacter》2020,25(4)
19.